Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

R-Nanochop Incorporating a TFR1-Targeted Doxorubicin Nanocarrier Is Superior to R-CHOP in a PDX Model of Diffuse Large B-Cell Lymphoma

Artavazd Arumov, BSc, Piumi Y. Liyanage, PhD, Asaad Trabolsi, MD, Evan R. Roberts, BS, Braulio C. L. B. Ferreira, BS, Austin D. Newsam, BS, Daniel Bilbao, PhD, Roger M. Leblanc, PhD, Jonathan H. Schatz, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-133482

Published: 2020

Journal Articles

Is There an Unequal Benefit of Autologous Stem Cell Transplant in Different Cytogenetic Groups of High Risk Patients with Multiple Myeloma: The University of Miami Experience

Fahmin Basher, MD PhD, Sandra Sanchez, MD, Jonathan H. Schatz, MD, James E. Hoffman, MD, Lazaros J. Lekakis, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-143266

Published: 2020

Journal Articles

Identification of Tractable Drug-like eIF4Al Inhibitors with Potent Anti-Tumor Activity

Tyler A. Cunningham, BS, Derek Essegian, BS, MS, Stephan Schürer, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 5760.

https://doi.org/10.1182/blood-2019-130494

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Artavazd Arumov, BSc, Piumi Y. Liyanage, BS, Asaad Trabolsi, MD, Lingxiao Li, PhD, Evan R. Roberts, BS, Daniel Bilbao, PhD, Roger M. LeBlanc, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 4061.

https://doi.org/10.1182/blood-2019-122599

Published: 2019

Journal Articles

NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation

Elias Drakos, MD PhD Prof., Konstantina Stathopoulou, MSc., Lingxiao Li, PhD, Daniel Bilbao, Vasiliki Leventaki, Pedro Farrajota Neves Da Silva, MD, Vasileios Atsaves, PhD, Anders Österborg, MD PhD, L. Jeffrey Medeiros, MD, Francisco Vega, MD PhD, Jonathan H. Schatz, MD, Francois Claret, PhD, George Z. Rassidakis, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 2796.

https://doi.org/10.1182/blood-2019-130457

Published: 2019

Journal Articles

CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients

Soumya Sundara Rajan, MSc, Lingxiao Li, PhD, Kranthi Kunkalla, Amit Dipak Amin, PhD, Nitin Agarwal, Francisco Vega, MD PhD, Jonathan H. Schatz, MD

Blood (2018) 132 (Supplement 1): 779.

https://doi.org/10.1182/blood-2018-99-114692

Published: 2018

Journal Articles

Novel Therapy for Aggressive Cutaneous T-Cell Lymphoma Leading to Complete Clinical Remission before Allogenic Stem Cell Transplantation

Nicolas Gallastegui Crestani, MD, Mohammed E. Ibrahim, CRPH, BCOP, BCPS, BCACP, Ayman M. Mohamed, PharmD, Paolo Romanelli, MD, Amer Beitinjaneh, MD MPH, MSc, Jonathan H. Schatz, MD

Blood (2018) 132 (Supplement 1): 5354.

https://doi.org/10.1182/blood-2018-99-117079

Published: 2018

Journal Articles

Computational Identification of Tractable Drug-like Inhibitors of eIF4A1

Derek Essegian, BS, MS, Tyler A. Cunningham, BS, Jonathan H. Schatz, MD, Stephan Schurer, PhD

Blood (2018) 132 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2018-99-116829

Published: 2018

Journal Articles

Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas

Alison J. Moskowitz, MD, Eric Jacobsen, MD, Jia Ruan, MD PhD, Jonathan H. Schatz, MD, Obadi Obadi, Kristin Motylinski, Christine Jarjies, MS, Natasha Galasso, Helen Hancock, NP, Theresa Davey, MPAS, Patricia Myskowski, MD, Ahmet Dogan, MD PhD, Giorgio Inghirami, MD, David M Weinstock, MD, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2018-99-112123

Published: 2018

Journal Articles

The Marine Natural Compound Elatol Is a Novel Protein Translation Inhibitor with Potent Activity Against Aggressive Non-Hodgkin Lymphomas

Tara Peters, BA, Joseph Tillotson, PhD, Sarah C Wilmore, BSc, Alison Yeomans, PhD, Graham Packham, PhD, Eli Chapman, PhD, Jonathan H. Schatz, MD, Lingxiao Li, PhD

Blood (2017) 130 (Supplement 1): 4112.

https://doi.org/10.1182/blood.V130.Suppl_1.4112.4112

Published: 2017

Journal Articles

NPM1-ALK Overexpression-Driven Toxicity in ALCL Is Partner Dependent and Mediated By STAT1 Antagonism of STAT3 Survival Signaling, Revealing a Novel Therapeutic Strategy

Soumya Sundara Rajan, M.Sc, Amit Dipak Amin, PhD, Lingxiao Li, PhD, Delphine C. M. Rolland, PharmD, PhD, Haiquan Li, PhD, Soham Puvvada, MD, Yves Lussier, MD, Megan S. Lim, MDPhD, Jonathan H. Schatz, MD

Blood (2017) 130 (Supplement 1): 2506.

https://doi.org/10.1182/blood.V130.Suppl_1.2506.2506

Published: 2017

Journal Articles

Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma

David A. Fruman, PhD, Jong-Hoon Scott Lee, B.S., Thanh-Trang T Vo, PhD, Shruti Bhatt, PhD, Jonathan H. Schatz, MD, Anthony Letai, MD PhD

Blood (2016) 128 (22): 3969.

https://doi.org/10.1182/blood.V128.22.3969.3969

Published: 2016

Journal Articles

Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis

Diana M Byrnes, MD MPH, Christopher R Dermarkarian, BS, Ryan Kahn, BA, MHS, Deukwoo Kwon, PhD, Fernando Vargas, MD, Judith Hurley, MD, Justin M. Watts, MD, Jonathan H. Schatz, MD, Ronan T Swords, MD PhD FRCPI, FRCPath

Blood (2016) 128 (22): 5973.

https://doi.org/10.1182/blood.V128.22.5973.5973

Published: 2016

Journal Articles

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Abhijeet Kumar, MD, Jose Guillen-Rodriguez, Jonathan H. Schatz, MD, Lora Inclan, Alfonso E Ayala, Xavier Rivera, Srinath Sundararajan, MD, Faiz Anwer, MD, Daruka Mahadevan, MD PhD, Daniel O. Persky, MD, Soham D. Puvvada, MD

Blood (2016) 128 (22): 1790.

https://doi.org/10.1182/blood.V128.22.1790.1790

Published: 2016

Journal Articles

Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation

Tara L. Peters, BA, Ana A Tula-Sanchez, PhD, Lingxiao Li, PhD, Praechompoo Pongtornpipat, BS, Mengdie WANG, BS, Nicolette BROWN, BS, Soham D. Puvvada, MD, Jonathan H. Schatz, MD

Blood (2014) 124 (21): 4496.

https://doi.org/10.1182/blood.V124.21.4496.4496

Published: 2014

Journal Articles

Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1

Lingxiao Li, PhD, Praechompoo Pongtornpipat, BS, Timothy Tiutan, BS, BA, Samantha L. Kendrick, PhD, Soyoung Park, MD, Daniel O Persky, MD, Lisa M. Rimsza, MD, Soham D. Puvvada, MD, Jonathan H. Schatz, MD

Blood (2014) 124 (21): 506.

https://doi.org/10.1182/blood.V124.21.506.506

Published: 2014

Journal Articles

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Soham D. Puvvada, MD, Daniel O. Persky, MD, Lora Inclan, Jonathan H. Schatz, MD, Ellen M Chase, Jose Guillen, D Roe, Thomas P. Miller, MD

Blood (2013) 122 (21): 4404.

https://doi.org/10.1182/blood.V122.21.4404.4404

Published: 2013

Journal Articles

Targeting MYC Expression With CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphom

Lingxiao Li, PhD, Praechompoo Pongtornpipat, Soham D. Puvvada, MD, Jonathan H. Schatz, MD

Blood (2013) 122 (21): 1831.

https://doi.org/10.1182/blood.V122.21.1831.1831

Published: 2013

Journal Articles

Induced Dependence On The ALK Kinase Inhibitor Crizotinib In Formerly Sensitive Anaplastic Large Cell Lymphoma Cells

Amin Dipak Amit, PhD, Praechompoo Pongtornpipat, Jonathan H. Schatz, MD

Blood (2013) 122 (21): 3842.

https://doi.org/10.1182/blood.V122.21.3842.3842

Published: 2013

NARROW

R-Nanochop Incorporating a TFR1-Targeted Doxorubicin Nanocarrier Is Superior to R-CHOP in a PDX Model of Diffuse Large B-Cell Lymphoma

Is There an Unequal Benefit of Autologous Stem Cell Transplant in Different Cytogenetic Groups of High Risk Patients with Multiple Myeloma: The University of Miami Experience

Identification of Tractable Drug-like eIF4Al Inhibitors with Potent Anti-Tumor Activity

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation

CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients

Novel Therapy for Aggressive Cutaneous T-Cell Lymphoma Leading to Complete Clinical Remission before Allogenic Stem Cell Transplantation

Computational Identification of Tractable Drug-like Inhibitors of eIF4A1

Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas

The Marine Natural Compound Elatol Is a Novel Protein Translation Inhibitor with Potent Activity Against Aggressive Non-Hodgkin Lymphomas

NPM1-ALK Overexpression-Driven Toxicity in ALCL Is Partner Dependent and Mediated By STAT1 Antagonism of STAT3 Survival Signaling, Revealing a Novel Therapeutic Strategy

Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma

Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation

Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Targeting MYC Expression With CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphom

Induced Dependence On The ALK Kinase Inhibitor Crizotinib In Formerly Sensitive Anaplastic Large Cell Lymphoma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only